No abstract available
Keywords:
BCR-ABL; T315I mutation; TKI; chronic myelogenous leukemia; dasatinib; imatinib; nilotinib; ponatinib; resistance.
MeSH terms
-
Apoptosis / drug effects*
-
Benzamides / therapeutic use
-
Benzamides / toxicity*
-
Cell Line, Tumor
-
Drug Resistance, Neoplasm / drug effects*
-
Fusion Proteins, bcr-abl / genetics
-
Fusion Proteins, bcr-abl / metabolism
-
Humans
-
Imatinib Mesylate
-
Imidazoles / therapeutic use
-
Imidazoles / toxicity*
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / metabolism
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
-
Mutation
-
Piperazines / therapeutic use
-
Piperazines / toxicity*
-
Protein Kinase Inhibitors / therapeutic use
-
Protein Kinase Inhibitors / toxicity*
-
Pyridazines / therapeutic use
-
Pyridazines / toxicity*
-
Pyrimidines / therapeutic use
-
Pyrimidines / toxicity*
Substances
-
Benzamides
-
Imidazoles
-
Piperazines
-
Protein Kinase Inhibitors
-
Pyridazines
-
Pyrimidines
-
ponatinib
-
Imatinib Mesylate
-
Fusion Proteins, bcr-abl